Base de dados : MEDLINE
Pesquisa : D09.698.373.200 [Categoria DeCS]
Referências encontradas : 2791 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 280 ir para página                         

  1 / 2791 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28132690
[Au] Autor:Oud MM; Tuijnenburg P; Hempel M; van Vlies N; Ren Z; Ferdinandusse S; Jansen MH; Santer R; Johannsen J; Bacchelli C; Alders M; Li R; Davies R; Dupuis L; Cale CM; Wanders RJA; Pals ST; Ocaka L; James C; Müller I; Lehmberg K; Strom T; Engels H; Williams HJ; Beales P; Roepman R; Dias P; Brunner HG; Cobben JM; Hall C; Hartley T; Le Quesne Stabej P; Mendoza-Londono R; Davies EG; de Sousa SB; Lessel D; Arts HH; Kuijpers TW
[Ad] Endereço:Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands. Electronic address: machteld.oud@radboudumc.nl.
[Ti] Título:Mutations in EXTL3 Cause Neuro-immuno-skeletal Dysplasia Syndrome.
[So] Source:Am J Hum Genet;100(2):281-296, 2017 Feb 02.
[Is] ISSN:1537-6605
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:EXTL3 regulates the biosynthesis of heparan sulfate (HS), important for both skeletal development and hematopoiesis, through the formation of HS proteoglycans (HSPGs). By whole-exome sequencing, we identified homozygous missense mutations c.1382C>T, c.1537C>T, c.1970A>G, and c.2008T>G in EXTL3 in nine affected individuals from five unrelated families. Notably, we found the identical homozygous missense mutation c.1382C>T (p.Pro461Leu) in four affected individuals from two unrelated families. Affected individuals presented with variable skeletal abnormalities and neurodevelopmental defects. Severe combined immunodeficiency (SCID) with a complete absence of T cells was observed in three families. EXTL3 was most abundant in hematopoietic stem cells and early progenitor T cells, which is in line with a SCID phenotype at the level of early T cell development in the thymus. To provide further support for the hypothesis that mutations in EXTL3 cause a neuro-immuno-skeletal dysplasia syndrome, and to gain insight into the pathogenesis of the disorder, we analyzed the localization of EXTL3 in fibroblasts derived from affected individuals and determined glycosaminoglycan concentrations in these cells as well as in urine and blood. We observed abnormal glycosaminoglycan concentrations and increased concentrations of the non-sulfated chondroitin disaccharide D0a0 and the disaccharide D0a4 in serum and urine of all analyzed affected individuals. In summary, we show that biallelic mutations in EXTL3 disturb glycosaminoglycan synthesis and thus lead to a recognizable syndrome characterized by variable expression of skeletal, neurological, and immunological abnormalities.
[Mh] Termos MeSH primário: Anormalidades Musculoesqueléticas/genética
N-Acetilglucosaminiltransferases/genética
Osteocondrodisplasias/genética
[Mh] Termos MeSH secundário: Alelos
Linhagem Celular
Linhagem Celular Tumoral
Condroitina/sangue
Condroitina/urina
Variações do Número de Cópias de DNA
Estudo de Associação Genômica Ampla
Glicosaminoglicanos/metabolismo
Seres Humanos
Anormalidades Musculoesqueléticas/diagnóstico
Mutação de Sentido Incorreto
Osteocondrodisplasias/diagnóstico
Imunodeficiência Combinada Severa/diagnóstico
Imunodeficiência Combinada Severa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (EXTL3 protein, human); 0 (Glycosaminoglycans); 9007-27-6 (Chondroitin); EC 2.4.1.- (N-Acetylglucosaminyltransferases)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170802
[Lr] Data última revisão:
170802
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170131
[St] Status:MEDLINE


  2 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27645998
[Au] Autor:Izumikawa T; Dejima K; Watamoto Y; Nomura KH; Kanaki N; Rikitake M; Tou M; Murata D; Yanagita E; Kano A; Mitani S; Nomura K; Kitagawa H
[Ad] Endereço:From the Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658-8558, Japan.
[Ti] Título:Chondroitin 4-O-Sulfotransferase Is Indispensable for Sulfation of Chondroitin and Plays an Important Role in Maintaining Normal Life Span and Oxidative Stress Responses in Nematodes.
[So] Source:J Biol Chem;291(44):23294-23304, 2016 10 28.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chondroitin sulfate (CS)/chondroitin (Chn) chains are indispensable for embryonic cell division and cytokinesis in the early developmental stages in Caenorhabditis elegans and mice, whereas heparan sulfate (HS) is essential for axon guidance during nervous system development. These data indicate that the fundamental functions of CS and HS are conserved from worms to mammals and that the function of CS/Chn differs from that of HS. Although previous studies have shown that C. elegans produces HS and non-sulfated Chn, whether the organism produces CS remains unclear. Here, we demonstrate that C. elegans produces a small amount of 4-O-sulfated Chn and report the identification of C41C4.1, an orthologue of the human chondroitin 4-O-sulfotransferase gene. Loss of C41C4.1 in C. elegans resulted in a decline in 4-O-sulfation of CS and an increase in the number of sulfated units in HS. C41C4.1 deletion mutants exhibited reduced survival rates after synchronization with sodium hypochlorite. Collectively, these results show for the first time that CS glycans are present in C. elegans and that the Chn 4-O-sulfotransferase responsible for the sulfation plays an important role in protecting nematodes from oxidative stress.
[Mh] Termos MeSH primário: Proteínas de Caenorhabditis elegans/metabolismo
Caenorhabditis elegans/enzimologia
Caenorhabditis elegans/crescimento & desenvolvimento
Sulfatos de Condroitina/metabolismo
Condroitina/metabolismo
Estresse Oxidativo
Sulfotransferases/metabolismo
[Mh] Termos MeSH secundário: Animais
Caenorhabditis elegans/genética
Proteínas de Caenorhabditis elegans/genética
Divisão Celular
Feminino
Heparitina Sulfato/metabolismo
Masculino
Deleção de Sequência
Sulfatos/metabolismo
Sulfotransferases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Caenorhabditis elegans Proteins); 0 (Sulfates); 9007-27-6 (Chondroitin); 9007-28-7 (Chondroitin Sulfates); 9050-30-0 (Heparitin Sulfate); EC 2.8.2.- (C41C4.1 protein, C elegans); EC 2.8.2.- (Sulfotransferases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160921
[St] Status:MEDLINE


  3 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27357024
[Au] Autor:Kantor ED; Zhang X; Wu K; Signorello LB; Chan AT; Fuchs CS; Giovannucci EL
[Ad] Endereço:Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
[Ti] Título:Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study.
[So] Source:Int J Cancer;139(9):1949-57, 2016 Nov 01.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recent epidemiologic evidence has emerged to suggest that use of glucosamine and chondroitin supplements may be associated with reduced risk of colorectal cancer (CRC). We therefore evaluated the association between use of these non-vitamin, non-mineral supplements and risk of CRC in two prospective cohorts, the Nurses' Health Study and Health Professionals Follow-up Study. Regular use of glucosamine and chondroitin was first assessed in 2002 and participants were followed until 2010, over which time 672 CRC cases occurred. Cox proportional hazards regression was used to estimate relative risks (RRs) within each cohort, and results were pooled using a random effects meta-analysis. Associations were comparable across cohorts, with a RR of 0.79 (95% CI: 0.63-1.00) observed for any use of glucosamine and a RR of 0.77 (95% CI: 0.59-1.01) observed for any use of chondroitin. Use of glucosamine in the absence of chondroitin was not associated with risk of CRC, whereas use of glucosamine + chondroitin was significantly associated with risk (RR: 0.77; 95% CI: 0.58-0.999). The association between use of glucosamine + chondroitin and risk of CRC did not change markedly when accounting for change in exposure status over follow-up (RR: 0.75; 95% CI: 0.58-0.96), nor did the association significantly vary by sex, aspirin use, body mass index, or physical activity. The association was comparable for cancers of the colon and rectum. Results support a protective association between use of glucosamine and chondroitin and risk of CRC. Further study is needed to better understand the chemopreventive potential of these supplements.
[Mh] Termos MeSH primário: Condroitina/administração & dosagem
Neoplasias Colorretais/epidemiologia
Glucosamina/administração & dosagem
Pessoal de Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Idoso
Condroitina/uso terapêutico
Suplementos Nutricionais
Estudos Epidemiológicos
Feminino
Seguimentos
Glucosamina/uso terapêutico
Inquéritos Epidemiológicos
Seres Humanos
Masculino
Meia-Idade
Modelos de Riscos Proporcionais
Estudos Prospectivos
Fatores de Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9007-27-6 (Chondroitin); N08U5BOQ1K (Glucosamine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160701
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.30250


  4 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27304775
[Au] Autor:Shaughnessy AF
[Ad] Endereço:Tufts University, Boston, MA, USA.
[Ti] Título:Chondroitin/Glucosamine Equal to Celecoxib for Knee Osteoarthritis.
[So] Source:Am Fam Physician;93(12):1032, 2016 Jun 15.
[Is] ISSN:1532-0650
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Artralgia/tratamento farmacológico
Celecoxib/uso terapêutico
Condroitina/uso terapêutico
Inibidores de Ciclo-Oxigenase 2/uso terapêutico
Combinação de Medicamentos
Glucosamina/uso terapêutico
Osteoartrite do Joelho/tratamento farmacológico
[Mh] Termos MeSH secundário: Artralgia/diagnóstico
Educação Médica Continuada
Seres Humanos
Osteoartrite do Joelho/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclooxygenase 2 Inhibitors); 0 (Drug Combinations); 9007-27-6 (Chondroitin); JCX84Q7J1L (Celecoxib); N08U5BOQ1K (Glucosamine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160616
[St] Status:MEDLINE


  5 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27018169
[Au] Autor:Stellavato A; Tirino V; de Novellis F; Della Vecchia A; Cinquegrani F; De Rosa M; Papaccio G; Schiraldi C
[Ad] Endereço:Department of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
[Ti] Título:Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes.
[So] Source:J Cell Biochem;117(9):2158-69, 2016 09.
[Is] ISSN:1097-4644
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cartilage tissue engineering, with in vitro expansion of autologus chondrocytes, is a promising technique for tissue regeneration and is a new potential strategy to prevent and/or treat cartilage damage (e.g., osteoarthritis). The aim of this study was (i) to investigate and compare the effects of new biotechnological chondroitin (BC) and a commercial extractive chondroitin sulfate (CS) on human chondrocytes in vitro culture; (ii) to evaluate the anti-inflammatory effects of the innovative BC compared to extractive CS. A chondrogenic cell population was isolated from human nasoseptal cartilage and in vitro cultures were studied through time-lapse video microscopy (TLVM), immunohistochemical staining and cytometry. In order to investigate the effect of BC and CS on phenotype maintainance, chondrogenic gene expression of aggrecan (AGN), of the transcriptor factor SOX9, of the types I and II collagen (COL1A1 and COL1A2), were quantified through transcriptional and protein evaluation at increasing cultivation time and passages. In addition to resemble the osteoarthritis-like in vitro model, chondrocytes were treated with IL-1ß and the anti-inflammatory activity of BC and CS was assessed using cytokines quantification by multiplex array. BC significantly enhances cell proliferation also preserving chondrocyte phenotype increasing type II collagen expression up to 10 days of treatment and reduces inflammatory response in IL-1ß treated chondrocytes respect to CS treated cells. Our results, taken together, suggest that this new BC is of foremost importance in translational medicine because it can be applied in novel scaffolds and pharmaceutical preparations aiming at cartilage pathology treatments such as the osteoarthritis. J. Cell. Biochem. 117: 2158-2169, 2016. © 2016 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Antígenos de Diferenciação/biossíntese
Condrócitos/metabolismo
Condroitina/química
Regulação da Expressão Gênica
Tecidos Suporte/química
[Mh] Termos MeSH secundário: Células Cultivadas
Condrócitos/citologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Differentiation); 9007-27-6 (Chondroitin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171111
[Lr] Data última revisão:
171111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160329
[St] Status:MEDLINE
[do] DOI:10.1002/jcb.25556


  6 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26993287
[Au] Autor:Flengsrud R
[Ad] Endereço:Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences (NMBU), N-1432, Ås, Norway. ragnar.flengsrud@nmbu.no.
[Ti] Título:Disaccharide analysis of chondroitin and heparin from farmed Atlantic salmon.
[So] Source:Glycoconj J;33(2):121-3, 2016 Apr.
[Is] ISSN:1573-4986
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The heparin disaccharides detected in farmed Atlantic salmon (Salmo salar) gills and intestines have, with one exception, been reported in porcine heparin. The relative amounts of disaccharides appear to be very different in the two species. Two chondroitin disaccharides with a proposed essential role in the zebrafish (Danio rerio) development and differentiation are detected in farmed Atlantic salmon. In addition, most of the chondroitin/dermatan sulfate and heparin disaccharides detected here have been reported in zebrafish, in support of the claims of the heparin presence in fish. The same chondroitin/dermatan disaccharides were detected in the bones of bony fishes. The rare disaccharide UA2S-GalNAc that was found in trace amounts in all 5 bony fishes was found in relative high amounts in gills and in significant amounts in intestines. The rare heparin disaccharide UA2S-GlcN was in relative highest amounts both in gills and intestines. In context with our previous reports, this communication suggests that glycosaminoglycans in farmed Atlantic salmon heparin need further studies in order to clarify structure and function.
[Mh] Termos MeSH primário: Condroitina
Dissacarídeos
Heparina
Salmo salar
[Mh] Termos MeSH secundário: Animais
Condroitina/química
Condroitina/isolamento & purificação
Dissacarídeos/análise
Dissacarídeos/química
Dissacarídeos/isolamento & purificação
Heparina/química
Heparina/isolamento & purificação
Relação Estrutura-Atividade
Peixe-Zebra
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Disaccharides); 9005-49-6 (Heparin); 9007-27-6 (Chondroitin)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160320
[St] Status:MEDLINE
[do] DOI:10.1007/s10719-016-9652-8


  7 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26876870
[Au] Autor:Jin P; Zhang L; Yuan P; Kang Z; Du G; Chen J
[Ad] Endereço:The Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, Wuxi 214122, China; School of Biotechnology, Jiangnan University, Wuxi 214122, China.
[Ti] Título:Efficient biosynthesis of polysaccharides chondroitin and heparosan by metabolically engineered Bacillus subtilis.
[So] Source:Carbohydr Polym;140:424-32, 2016 Apr 20.
[Is] ISSN:1879-1344
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chondroitin and heparosan, important polysaccharides and key precursors of chondroitin sulfate and heparin/heparan sulfate, have drawn much attention due to their wide applications in many aspects. In this study, we designed two independent synthetic pathways of chondroitin and heparosan in food-grade Bacillus subtilis, integrating critical synthases genes derived from Escherichia coli into B. subtilis genome. By RT-PCR analysis, we confirmed that synthases genes transcripted an integral mRNA chain, suggesting co-expression. In shaken flask, chondroitin and heparosan were produced at a level of 1.83gL(-1) and 1.71gL(-1), respectively. Since B. subtilis endogenous tuaD gene encodes the limiting factor of biosynthesis, overexpressing tuaD resulted in enhanced chondroitin and heparosan titers, namely 2.54gL(-1) and 2.65gL(-1). Moreover, production reached the highest peaks of 5.22gL(-1) and 5.82gL(-1) in 3-L fed-batch fermentation, respectively, allowed to double the production that in shaken flask. The weight-average molecular weight of chondroitin and heparosan from B. subtilis E168C/pP43-D and E168H/pP43-D were 114.07 and 67.70kDa, respectively. This work provided alternative safer synthetic pathways for metabolic engineering of chondroitin and heparosan in B. subtilis and a useful approach for enhancing production, which can be optimized for further improvement.
[Mh] Termos MeSH primário: Bacillus subtilis/genética
Bacillus subtilis/metabolismo
Condroitina/biossíntese
Dissacarídeos/biossíntese
Engenharia Metabólica
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Técnicas de Cultura Celular por Lotes
Condroitina/química
DNA Recombinante/genética
Dissacarídeos/química
Fermentação
Peso Molecular
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (DNA, Recombinant); 0 (Disaccharides); 0 (heparosan); 9007-27-6 (Chondroitin)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160216
[St] Status:MEDLINE


  8 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26582078
[Au] Autor:Mizumoto S; Yamada S; Sugahara K
[Ad] Endereço:Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan.
[Ti] Título:Mutations in Biosynthetic Enzymes for the Protein Linker Region of Chondroitin/Dermatan/Heparan Sulfate Cause Skeletal and Skin Dysplasias.
[So] Source:Biomed Res Int;2015:861752, 2015.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Glycosaminoglycans, including chondroitin, dermatan, and heparan sulfate, have various roles in a wide range of biological events such as cell signaling, cell proliferation, tissue morphogenesis, and interactions with various growth factors. Their polysaccharides covalently attach to the serine residues on specific core proteins through the common linker region tetrasaccharide, -xylose-galactose-galactose-glucuronic acid, which is produced through the stepwise addition of respective monosaccharides by four distinct glycosyltransferases. Mutations in the human genes encoding the glycosyltransferases responsible for the biosynthesis of the linker region tetrasaccharide cause a number of genetic disorders, called glycosaminoglycan linkeropathies, including Desbuquois dysplasia type 2, spondyloepimetaphyseal dysplasia, Ehlers-Danlos syndrome, and Larsen syndrome. This review focused on recent studies on genetic diseases caused by defects in the biosynthesis of the common linker region tetrasaccharide.
[Mh] Termos MeSH primário: Anormalidades Craniofaciais/genética
Nanismo/genética
Síndrome de Ehlers-Danlos/genética
Glicosiltransferases/genética
Instabilidade Articular/genética
Ossificação Heterotópica/genética
Osteocondrodisplasias/genética
Polidactilia/genética
[Mh] Termos MeSH secundário: Proliferação Celular/genética
Condroitina/metabolismo
Anormalidades Craniofaciais/enzimologia
Anormalidades Craniofaciais/metabolismo
Dermatan Sulfato/metabolismo
Nanismo/enzimologia
Nanismo/metabolismo
Síndrome de Ehlers-Danlos/enzimologia
Síndrome de Ehlers-Danlos/metabolismo
Heparitina Sulfato/metabolismo
Seres Humanos
Instabilidade Articular/enzimologia
Instabilidade Articular/metabolismo
Morfogênese/genética
Mutação
Ossificação Heterotópica/enzimologia
Ossificação Heterotópica/metabolismo
Osteocondrodisplasias/enzimologia
Osteocondrodisplasias/metabolismo
Polidactilia/enzimologia
Polidactilia/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
24967-94-0 (Dermatan Sulfate); 9007-27-6 (Chondroitin); 9050-30-0 (Heparitin Sulfate); EC 2.4.- (Glycosyltransferases)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151123
[Lr] Data última revisão:
151123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151120
[St] Status:MEDLINE
[do] DOI:10.1155/2015/861752


  9 / 2791 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26576862
[Au] Autor:Zeng C; Wei J; Li H; Wang YL; Xie DX; Yang T; Gao SG; Li YS; Luo W; Lei GH
[Ad] Endereço:Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan Province, China, 410008.
[Ti] Título:Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee.
[So] Source:Sci Rep;5:16827, 2015 Nov 18.
[Is] ISSN:2045-2322
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study aimed to investigate the effectiveness and safety of glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of knee osteoarthritis (OA). PubMed, Embase and Cochrane Library were searched through from inception to February 2015. A total of 54 studies covering 16427 patients were included. Glucosamine plus chondroitin, glucosamine alone, and celecoxib were all more effective than placebo in pain relief and function improvement. Specifically, celecoxib is most likely to be the best treatment option, followed by the combination group. All treatment options showed clinically significant improvement from baseline pain, but only glucosamine plus chondroitin showed clinically significant improvement from baseline function. In terms of the structure-modifying effect, both glucosamine alone and chondroitin alone achieved a statistically significant reduction in joint space narrowing. Although no significant difference was observed among the five options with respect to the three major adverse effects (withdrawal due to adverse events, serious adverse events and the number of patients with adverse events), the additional classical meta-analysis showed that celecoxib exhibited a higher rate of gastrointestinal adverse effect comparing with the placebo group. The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
[Mh] Termos MeSH primário: Celecoxib/uso terapêutico
Condroitina/uso terapêutico
Glucosamina/uso terapêutico
Osteoartrite do Joelho/tratamento farmacológico
[Mh] Termos MeSH secundário: Artralgia/tratamento farmacológico
Artralgia/etiologia
Celecoxib/efeitos adversos
Condroitina/efeitos adversos
Quimioterapia Combinada
Glucosamina/efeitos adversos
Seres Humanos
Razão de Chances
Osteoartrite do Joelho/complicações
Osteoartrite do Joelho/fisiopatologia
Manejo da Dor
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
9007-27-6 (Chondroitin); JCX84Q7J1L (Celecoxib); N08U5BOQ1K (Glucosamine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151124
[Lr] Data última revisão:
151124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151119
[St] Status:MEDLINE
[do] DOI:10.1038/srep16827


  10 / 2791 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26218551
[Au] Autor:Bhotmange DU; Singhal RS
[Ad] Endereço:Food Engineering and Technology Department, Institute of Chemical Technology, Nathalal Parekh Marg, Mumbai, India.
[Ti] Título:Identification of chondroitin-like molecules from biofilm isolates Exiguobacterium indicum A11 and Lysinibacillus sp. C13.
[So] Source:J Appl Microbiol;119(4):1046-56, 2015 Oct.
[Is] ISSN:1365-2672
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: The study aims to investigate whether the bacteria from biofilms can produce chondroitin-like molecules (CLMs). METHODS AND RESULTS: Chondroitin belongs to the class of glycosaminoglycans. Forty bacteria from biofilms were isolated and screened for the production of glycosaminoglycans. Two isolates A11 and C13 produced 43 and 26 mg l(-1) of chondroitinase AC II degradable glycosaminoglycans, respectively, suggesting the possibility of production of CLMs by them. These isolates were identified using 16S rDNA sequencing technique and fatty acid methyl ester analysis. These were recognized as Exiguobacterium indicum A11 (NCIM 5531) and Lysinibacillus sp. C13 (NCIM 5532) respectively. These strains were also characterized using polar lipid content and biochemical tests. The identity of the glycosaminoglycans produced was further confirmed using agarose gel electrophoresis, fourier transform infrared spectroscopy and proton nuclear magnetic resonance spectroscopy. CONCLUSIONS: Prokaryotic biofilms were found to be a good source of bacteria synthesizing CLMs. Two wild strains producing significant amount of the same were identified and characterized. SIGNIFICANCE AND IMPACT OF THE STUDY: This is the first study exploring natural biofilms for the production of the therapeutic molecule, chondroitin/glycosaminoglycan. These isolates may be prospective new alternatives to recombinant strains that are reported for the production of chondroitin/glycoaminoglycan at an industrial scale. The production by these wild strains could be commercially attractive if the production is higher and/or can be improved further by strain improvement/process engineering. Further, these are new additions to the scientific literature on glycosaminoglycan-producing micro-organisms.
[Mh] Termos MeSH primário: Bacillaceae/fisiologia
Condroitina/biossíntese
[Mh] Termos MeSH secundário: Bacillaceae/química
Bacillaceae/genética
Bacillaceae/isolamento & purificação
Biofilmes
Condroitina/química
DNA Ribossômico/genética
Espectroscopia de Infravermelho com Transformada de Fourier
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (DNA, Ribosomal); 9007-27-6 (Chondroitin)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150921
[Lr] Data última revisão:
150921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150729
[St] Status:MEDLINE
[do] DOI:10.1111/jam.12914



página 1 de 280 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde